Fox Run Management’s ADMA Biologics ADMA Stock Holding History

Fox Run Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$339K	Sell	40,526 -33,465	-45%	-$305K	0.06%	625
2026 Q1	$677K	Buy	73,991 +49,095	+197%	+$775K	0.12%	310
2025 Q4	$454K	Buy	24,896 +8,644	+53%	+$146K	0.07%	534
2025 Q3	$238K	Sell	16,252 -9,121	-36%	-$156K	0.04%	755
2025 Q2	$462K	Sell	25,373 -8,933	-26%	-$182K	0.08%	497
2025 Q1	$681K	Buy	34,306 +15,189	+79%	+$263K	0.11%	348
2024 Q4	$328K	Buy	+19,117	New	+$360K	0.06%	600
2024 Q3	–	Sell	-15,892	Closed	-$178K	–	770
2024 Q2	$178K	Buy	+15,892	New	+$133K	0.03%	687

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Fox Run Management's ADMA Position: Q2 2026 in Review

Fox Run Management reduced its ADMA Biologics (ADMA) stake by 45% in Q2 2026, selling an estimated $305K and leaving 40,526 shares worth $339K. The position accounts for 0.06% of the portfolio, ranked #625.

Fox Run Management first reported a position in ADMA in Q2 2024 and has held it in 8 quarters since. The position peaked at $681K in Q1 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Fox Run Management held 40,526 shares of ADMA Biologics worth $339K as of Q2 2026.
Fox Run Management sold 33,465 ADMA Biologics shares in Q2 2026, an estimated $305K.
ADMA Biologics made up 0.06% of Fox Run Management's portfolio in Q2 2026, its #625 holding.
Fox Run Management first reported a position in ADMA Biologics in Q2 2024 and has held it in 8 quarters since.
Fox Run Management's ADMA Biologics position peaked at $681K in Q1 2025.
323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.